Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Withdrawn Phase 2 Interventional

CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV

NCT07090174
View directory record Official record
Conditions
HPV Associated Cancers, HIV (Human Immunodeficiency Virus), Anal Cancer, Cervical Cancer, HPV 16 Infection
Interventions
PDS0101
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serological Surveillance for COVID-19 in Central North Carolina

NCT04490174
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
643 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals

NCT00393276
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Twinrix, Decavac
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376
View directory record Official record
Conditions
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Silymarin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

NCT00298350
View directory record Official record
Conditions
HIV, HIV-1, Human Immunodeficiency Virus
Interventions
GS-9137 - A Novel HIV-1 Integrase Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance

NCT05764174
View directory record Official record
Conditions
Vaccination Refusal, COVID-19
Interventions
Factual messages, Narrative message, Mixed message
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Not applicable Interventional

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

NCT04168008
View directory record Official record
Conditions
HIV/AIDS
Interventions
WISH Adherence, WISH Parenting
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS

NCT00000640
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Primaquine, Sulfamethoxazole-Trimethoprim, Dapsone, Clindamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
32
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Not applicable Interventional

The Effects of Zidovudine on the Blood of HIV-Infected Patients

NCT00000965
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 31, 2026, 2:43 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Bioaerosol Sampling Device (BSD) Clinical Study

NCT06047067
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Cantor BioConnect, Inc.
Network
Eligibility
5 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
South Gate, California • Hollywood, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Romidepsin Plus 3BNC117 Phase 2a Study

NCT02850016
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
3BNC117, Romidepsin
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

NCT01806909
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-H5-Vtn
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 31, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire

NCT06765187
View directory record Official record
Conditions
Influenza Immunization, Health Volunteers
Interventions
Trivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

NCT00000918
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 31, 2026, 2:43 AM EDT
Suspended Phase 1 Interventional

The DART DELIVER-02 Study

NCT07217379
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
MGD020, MGD014, Vorinostat, Temporary treatment interruption
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

NCT00002146
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions
Magnesium sulfate, Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503
View directory record Official record
Conditions
COVID-19
Interventions
JINZHEN Granules for Oral Solution, Placebo
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

NCT01196988
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
3,027 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
14
States / cities
Sacramento, California • Boca Raton, Florida • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

NCT00119379
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
NucleomaxX, Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

NCT01990846
View directory record Official record
Conditions
Influenza
Interventions
Flufirvitide 3, Placebo for Flufirvitide-3
Drug
Lead sponsor
Autoimmune Technologies, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 31, 2026, 2:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

China Adherence Through Technology Study

NCT01722552
View directory record Official record
Conditions
Medication Adherence
Interventions
adherence feedback, standard of care
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 31, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Intervention Development

NCT04077138
View directory record Official record
Conditions
HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions
Not listed
Lead sponsor
Hektoen Institute for Medical Research
Other
Eligibility
15 Years to 24 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 31, 2026, 2:43 AM EDT